Illumina (NASDAQ:ILMN) Stock Rating Upgraded by Royal Bank Of Canada

Illumina (NASDAQ:ILMN) was upgraded by research analysts at Royal Bank Of Canada to a “moderate buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other research firms also recently issued reports on ILMN. JPMorgan Chase & Co. raised their price target on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Weiss Ratings downgraded shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Robert W. Baird set a $137.00 price target on shares of Illumina in a research report on Friday, February 6th. Barclays raised their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Finally, Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $137.75.

Illumina Trading Down 0.5%

Illumina stock opened at $142.54 on Thursday. The firm’s 50-day moving average is $128.58 and its 200-day moving average is $129.52. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina has a 1 year low of $78.55 and a 1 year high of $155.53. The company has a market cap of $21.57 billion, a P/E ratio of 25.92, a PEG ratio of 2.37 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm posted $0.97 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts expect that Illumina will post 5.2 earnings per share for the current year.

Insider Activity at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Keith A. Meister sold 104,393 shares of Illumina stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the sale, the director owned 3,500,048 shares in the company, valued at approximately $508,696,976.32. This represents a 2.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 332,530 shares of company stock worth $48,303,655 in the last ninety days. 2.90% of the stock is owned by insiders.

Institutional Trading of Illumina

Several hedge funds have recently bought and sold shares of ILMN. Elyxium Wealth LLC bought a new stake in Illumina in the 4th quarter valued at about $25,000. Board of the Pension Protection Fund bought a new stake in Illumina in the 4th quarter valued at about $26,000. Creative Capital Management Investments LLC lifted its position in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. bought a new stake in Illumina in the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in Illumina in the 4th quarter valued at about $26,000. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.